First Read: China Pharmaceutical Retail Sector "Regulatory talks spur ma..."

Research evidence excerpt

First Read: China Pharmaceutical Retail Sector "Regulatory talks spur ma..."

Global Research

18 May 2026ab

First Read

EquitiesChina Pharmaceutical Retail Sector

Regulatory talks spur market concerns; we China

expect limited financial impact Healthcare

Henry Liu, CFA

Analyst

henry-za.liu@ubs.com

What happened? +86-105-832 8509

On May 16, the National Healthcare Security Administration (NHSA) announced that it Chen Chen, PhD

has recently held regulatory talks with relevant executives from pharmacy chains such as Analyst

Laobaixing (LBX), Yangtianhe, Yifeng, Henan ZhangZhongJing, with regards to misuse S1460520100001

of the gov. medical insurance fund. Issues identified via NHSA's unannounced chen-zb.chen@ubs.com

inspections include non-compliant usage of insurance funds to cover sales of non- +86-10-5832 8201

reimbursable products or diagnosis and medical treatment. The NHSA urged the above Judy Xie

chains to carry out rectification and pursue accountability, organise internal compliance Associate

trainings and improve compliance control systems. In addition, an article reported by S1460125100001

media on May 14th suggests tightening regulations over GLP-1 sales at offline judy.xie@ubs.com

pharmacies in Shanghai (see feedback from channel checks and corporates, as well as +86-105-832 8006

our assessment of potential impact here). As of noon today, listed pharmacy chains we

cover saw their stock prices drop 4-8%.

Impact to listed companies

According to LBX and Yifeng: 6 LBX stores and 1 Yifeng franchised store were impacted,

and the amount of misused funds were very small. The companies have already

implemented internal rectification, and they expect no further penalties from regulators.

As things stand, we expect limited potential impact on the companies' financials.